Ultragenyx Analyst Day Presentation

COMMERCIAL DEVELOPMENT Focused on three therapeutic areas BONE ENDOCRINE Ph 3 Ph 2 INBORN ERRORS OF METABOLISM Ph 3 Ph 3 Ph 3 UX143 UX701 Osteogenesis Imperfecta Wilson DTX301 OTC DTX401 GSDla UX111 MPS IIIA CRYSVITAⓇ burosumab R CRYSVITAⓇ burosumab XLH Confidential and Proprietary TIO Mepsevii (vestronidase alfa-vjbk) injection DOJOLVI TRIHEPTANOIN Oral Liquid MPS VII LC-FAOD Evkeeza (evinacumab-dgnb) Injection HoFH CNS / MUSCLE Ph 2 GTX-102 Angelman Syndrome Preclinical (Disclosed) UX810 Duchenne UX055 CDD ultragenyx

View entire presentation